- Home
- ACHC vs TSHA Comparison
ACHC vs TSHA Comparison
Compare ACHC & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACHC | TSHA |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACHC | TSHA |
|---|---|---|
| Price | $14.46 | $5.87 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 9 |
| Target Price | ★ $24.00 | $10.22 |
| AVG Volume (30 Days) | 3.6M | ★ 4.1M |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.18 | N/A |
| Revenue | ★ $3,265,548,000.00 | $6,310,000.00 |
| Revenue This Year | $6.50 | N/A |
| Revenue Next Year | $4.38 | N/A |
| P/E Ratio | $12.22 | ★ N/A |
| Revenue Growth | ★ 4.58 | N/A |
| 52 Week Low | $12.63 | $1.05 |
| 52 Week High | $47.08 | $5.95 |
Technical Indicators
Market Signals| Indicator | ACHC | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | 37.07 | 64.79 |
| Support Level | $13.95 | $5.37 |
| Resistance Level | $14.94 | $5.95 |
| Average True Range (ATR) | 0.85 | 0.34 |
| MACD | 0.22 | 0.03 |
| Stochastic Oscillator | 62.67 | 95.15 |
Price Performance
Historical ComparisonAbout ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.